Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
about
The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillanceManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes.Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesEarly lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.The myelodysplastic syndromes: the era of understanding.The Interplay between PP2A and microRNAs in Leukemia.Where Does Lenalidomide Fit in Non-del(5q) MDS?Current Role of Genetics in Hematologic Malignancies.Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.
P2860
Q26739246-266EA8F4-C7EB-4641-9486-5E5E9697F42AQ30235355-8D984A73-9D4C-4B7C-BEEB-51586AA58837Q33431466-186CCFD8-98A4-4952-A0A9-386030332712Q33987086-92B4BF8D-22F5-4E04-8384-E6695479C0ACQ34783754-7A14F974-6859-497B-906F-16410F53B175Q37441528-14BF354D-665E-4A41-AFF8-4376F4C998DEQ38245878-92A42DC4-DEDE-4F7F-80ED-F174D7D7D062Q38370368-E527C528-7B5A-4823-9FD2-36F7FE81355FQ38546273-6B1539E7-E3C3-4614-89A6-30547988B484Q38726143-4C56A8E6-6761-4D6B-9B29-E9D2159CB175Q38758162-A7F18D60-7D7F-47BA-AE31-C91F1BBC1C78Q42696060-5F767CCB-B214-4251-AC59-4A887E8A3E02Q52777531-D860E70D-B556-4A0F-B40C-B7090B88FAB1Q55364989-9F181B87-6378-4EEA-8854-CFEBD87EDDE9
P2860
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Lenalidomide as a disease-modi ...... of action to clinical outcomes
@en
type
label
Lenalidomide as a disease-modi ...... of action to clinical outcomes
@en
prefLabel
Lenalidomide as a disease-modi ...... of action to clinical outcomes
@en
P2093
P2860
P50
P921
P1433
P1476
Lenalidomide as a disease-modi ...... of action to clinical outcomes
@en
P2093
Ghulam J Mufti
Kyle J MacBeth
P2860
P356
10.1007/S00277-013-1863-5
P577
2013-09-10T00:00:00Z
2014-01-01T00:00:00Z